We caught up with Anthony Philippakis, Chief Data Officer at The Broad Institute, and Susan Tousi, Senior Vice President of Product Development at Illumina, at the 2018 Bio-IT World Conference in Boston, to speak about what this acquisition means for genomic analysis. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, ...

Dr. Martin Chavez, Chief of Maternal Fetal Medicine at Winthrop University Hospital discusses why he recommends noninvasive prenatal testing (NIPT). He notes that its accuracy, sensitivity, and specificity are incredible compared to what has historically been available. He concludes that NIPT provides both physicians and patients with the confidence and early results they need. Subscribe to the I...

The VeriSeq™ NIPT solution from Illumina is a powerful screening test that can provide information on the health of a developing fetus using a simple maternal blood draw. Cell-free DNA, released by placental cells during pregnancy, can be used to test for selected chromosomal abnormalities in the fetus as early as 10 weeks’ gestation. Find out how this NIPT workflow detects aneuploidy in three sim...

It’s time to rethink NIPT. Introducing the VeriSeq NIPT solution, a powerful screening test from Illumina that can provide information on the health of a developing fetus using a simple maternal blood draw. Watch how one tube of blood is processed into uniquely tagged cfDNA libraries. See how cfDNA libraries are sequenced as paired reads, and discover how paired reads generate confident calls—all ...

If you think noninvasive prenatal testing (NIPT) is too complicated, think again. Discover VeriSeq NIPT, a different approach from Illumina. Built on industry-leading technology, the solution is simple, fast, and automated. Transform your lab with the revolutionary workflow. For In Vitro Diagnostic Use. Not available in all countries and regions. QB 5701 Subscribe to the Illumina video channel h...